- Home
- MOB vs CTSO Comparison
MOB vs CTSO Comparison
Compare MOB & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOB
- CTSO
- Stock Information
- Founded
- MOB 2008
- CTSO 1997
- Country
- MOB Israel
- CTSO United States
- Employees
- MOB N/A
- CTSO N/A
- Industry
- MOB Real Estate Investment Trusts
- CTSO Medical/Dental Instruments
- Sector
- MOB Real Estate
- CTSO Health Care
- Exchange
- MOB Nasdaq
- CTSO Nasdaq
- Market Cap
- MOB 53.1M
- CTSO 61.7M
- IPO Year
- MOB 2022
- CTSO N/A
- Fundamental
- Price
- MOB $7.70
- CTSO $0.91
- Analyst Decision
- MOB Strong Buy
- CTSO Buy
- Analyst Count
- MOB 1
- CTSO 2
- Target Price
- MOB $10.00
- CTSO $5.50
- AVG Volume (30 Days)
- MOB 564.4K
- CTSO 124.2K
- Earning Date
- MOB 08-12-2025
- CTSO 11-06-2025
- Dividend Yield
- MOB N/A
- CTSO N/A
- EPS Growth
- MOB N/A
- CTSO N/A
- EPS
- MOB N/A
- CTSO N/A
- Revenue
- MOB $2,826,361.00
- CTSO $36,107,520.00
- Revenue This Year
- MOB N/A
- CTSO $11.93
- Revenue Next Year
- MOB N/A
- CTSO $21.22
- P/E Ratio
- MOB N/A
- CTSO N/A
- Revenue Growth
- MOB N/A
- CTSO 20.18
- 52 Week Low
- MOB $0.97
- CTSO $0.71
- 52 Week High
- MOB $7.84
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- MOB 76.98
- CTSO 42.60
- Support Level
- MOB $5.78
- CTSO $0.94
- Resistance Level
- MOB $7.80
- CTSO $1.04
- Average True Range (ATR)
- MOB 0.76
- CTSO 0.05
- MACD
- MOB 0.14
- CTSO -0.00
- Stochastic Oscillator
- MOB 94.70
- CTSO 24.64
About MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.